Revaccination with different COVID-19 vaccine; Interchange of vaccine products; COVID-19 with RINVOQ (UPADACITINIB); This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19 with RINVOQ (UPADACITINIB)), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect products included non-company products COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 vaccination and UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis (Moderate to severe.).   On 24-Mar-2021, the patient received first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (Intramuscular) 1 dosage form. On 20-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started UPADACITINIB (RINVOQ) (Oral) 1 dosage form. On 20-Jan-2022, the patient experienced COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). In 2022, the patient experienced COVID-19 (COVID-19 with RINVOQ (UPADACITINIB)). At the time of the report, COVID-19 (COVID-19 with RINVOQ (UPADACITINIB)) was resolving and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications was reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  The reporter's causality for the events of COVID-19 with RINVOQ (UPADACITINIB) was not related for Rinvoq and Possible for Janssen COVID-19 Vaccine.  No treatment drug details was reported.  Company Comment: This is a spontaneous case concerning  a  66-year-old, female patient with no relevant medical history, who experienced the unexpected non-serious events of (AESI) COVID-19, COVID-19 immunisation, Interchange of vaccine products. The events COVID-19 immunization and Interchange of vaccine products occurred on the same say after the third dose of mRNA-1273 Vaccine.  The exact date of onset of the event COVID-19 was not specified, hence latency could not be assessed. It was reported that Co suspect drugs Janssen Covid-19 vaccine and Updadacitinib are co-suspect drugs.  No further details on clinical course, lab test results and treatment received were reported. Outcome of the event Covid-19 resolving, while events COVID-19 immunization and Interchange of vaccine products outcome was unknown. The benefit-risk relationship of mRNA-1273 Vaccine, is not affected by this report.; Sender's Comments: This is a spontaneous case concerning  a  66-year-old, female patient with no relevant medical history, who experienced the unexpected non-serious events of COVID-19, COVID-19 immunisation, Interchange of vaccine products. The events COVID-19 immunization and Interchange of vaccine products occurred on the same say after the third dose of mRNA-1273 Vaccine.  The exact date of onset of the event COVID-19 was not specified, hence latency could not be assessed. It was reported that Co suspect drugs Janssen Covid-19 vaccine and Updadacitinib are co-suspect drugs.  No further details on clinical course, lab test results and treatment received were reported. Outcome of the event Covid-19 resolving, while events COVID-19 immunization and Interchange of vaccine products outcome was unknown. The benefit-risk relationship of mRNA-1273 Vaccine, is not affected by this report.